Marin de Jong1, Andrea van der Meulen-de Jong, Mariëlle Romberg-Camps, Juliette Degens, Marco Becx, Tineke Markus, Henny Tomlow, Mia Cilissen, Nienke Ipenburg, Marthe Verwey, Laurence Colautti-Duijsens, Wim Hameeteman, Ad Masclee, Daisy Jonkers, Marieke Pierik. 1. *Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, Netherlands; †NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands; ‡Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, Netherlands; §Department of Gastroenterology and Hepatology, Zuyderland Medical Center, Sittard-Geleen, Netherlands; ‖Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, Netherlands; ¶CCUVN, Dutch IBD Patients Organization, Woerden, Netherlands; and **N-NIC, Nurses Network IBD Care, Nurses Initiative on Crohn and Colitis, Utrecht, Netherlands.
Abstract
BACKGROUND: Tight control of disease activity, medication side effects, and adherence are crucial to prevent disease complications and improve quality of life in patients with inflammatory bowel disease (IBD). The chronic nature and increasing incidence of IBD demand health care innovations to guarantee future high-quality care. Previous research proved that integrated care by telemedicine can improve outcomes of chronic diseases. Currently available IBD telemedicine tools focus on specific patient subgroups. Therefore, we aimed to (1) develop a telemedicine system suitable for all patients with IBD in everyday practice and (2) to test this system's feasibility. METHODS: With a structured iterative process between patients, dietitians, IBD nurse-specialists, and gastroenterologists, myIBDcoach was developed. During 3 months, myIBDcoach's feasibility was tested by 30 consecutive outpatients with IBD of 3 hospitals. Thereafter, patients and health care providers completed a questionnaire covering satisfaction, accessibility, and experiences with myIBDcoach. RESULTS:MyIBDcoach enables continuous home-monitoring of patients with IBD and optimizes disease knowledge and communication between patients and health care providers. Besides disease activity, medication adherence, and side effects, myIBDcoach monitors malnutrition, smoking, quality of life, fatigue, life-events, work participation, stress, and anxiety and depression and provides e-learnings for patient empowerment. Patients graded the system with a mean of 7.8 of 10, and 93% would recommend myIBDcoach to other patients. CONCLUSIONS: We developed myIBDcoach, which enables integrated care for all patients with IBD, regardless of disease severity or medication use. The feasibility study showed high satisfaction and compliance of patients and health care providers. To study myIBDcoach's efficacy, a multicenter randomized controlled trial has been initiated.
RCT Entities:
BACKGROUND: Tight control of disease activity, medication side effects, and adherence are crucial to prevent disease complications and improve quality of life in patients with inflammatory bowel disease (IBD). The chronic nature and increasing incidence of IBD demand health care innovations to guarantee future high-quality care. Previous research proved that integrated care by telemedicine can improve outcomes of chronic diseases. Currently available IBD telemedicine tools focus on specific patient subgroups. Therefore, we aimed to (1) develop a telemedicine system suitable for all patients with IBD in everyday practice and (2) to test this system's feasibility. METHODS: With a structured iterative process between patients, dietitians, IBD nurse-specialists, and gastroenterologists, myIBDcoach was developed. During 3 months, myIBDcoach's feasibility was tested by 30 consecutive outpatients with IBD of 3 hospitals. Thereafter, patients and health care providers completed a questionnaire covering satisfaction, accessibility, and experiences with myIBDcoach. RESULTS: MyIBDcoach enables continuous home-monitoring of patients with IBD and optimizes disease knowledge and communication between patients and health care providers. Besides disease activity, medication adherence, and side effects, myIBDcoach monitors malnutrition, smoking, quality of life, fatigue, life-events, work participation, stress, and anxiety and depression and provides e-learnings for patient empowerment. Patients graded the system with a mean of 7.8 of 10, and 93% would recommend myIBDcoach to other patients. CONCLUSIONS: We developed myIBDcoach, which enables integrated care for all patients with IBD, regardless of disease severity or medication use. The feasibility study showed high satisfaction and compliance of patients and health care providers. To study myIBDcoach's efficacy, a multicenter randomized controlled trial has been initiated.
Authors: Andrew Lukas Yin; David Hachuel; John P Pollak; Ellen J Scherl; Deborah Estrin Journal: J Med Internet Res Date: 2019-08-19 Impact factor: 5.428
Authors: Laura Janssen; Mariëlle Romberg-Camps; Ad van Bodegraven; Jeoffrey Haans; Michèl Aquarius; Paul Boekema; Tamara Munnecom; Lloyd Brandts; Manuela Joore; Adrian Masclee; D Jonkers; M Pierik Journal: BMJ Open Date: 2021-05-04 Impact factor: 2.692